CD274 and neoplasm: The phase III trial IMpassion130, which tested the combination of atezolizumab with nab-paclitaxel in the first-line metastatic setting, established a potential role of immunotherapy in patients with PD-L1-positive TNBC, defined as ≥1% in tumor-infiltrating immune cells based on the IHC SP142 assay135,136.